Nintil

Links (91)

2025-09-13 · 00:00 UTC ·1 min read

Brief

Nintil's Links (91) (2025-09-13) aggregates 91 items spanning Alzheimer’s research—lithium orotate, amyloid‑cascade defense noting Alnylam’s ‘no NfL change’ result, and a company’s Phase‑1 AD trial planned in 2025—plus tech, RCT biomarker failures, and AI commentary.

Why it matters

Nintil's Links (91) (2025-09-13) aggregates 91 items and highlights Alzheimer's developments: lithium orotate reported helpful, a defense of the amyloid cascade citing Alnylam's recent failure with 'no NfL change', and a company planning a Phase‑1 AD drug trial later in 2025.

Key details

  • Other notable entries include steep declines in electronics component costs, Zvi Mowshowitz on LLM adoption, an RCT where epigenetic proxies failed to detect LDL changes, proposals to repurpose HIV drugs for anti‑aging, and a first‑person Phase‑1 clinical trial report.
Source evidence

title: Links (91)
contenttype: article
publication: Nintil
published: 2025-09-13T00:00:00+00:00
sourceurl: https://nintil.com/links-91/

word_count: 249

Lithium orotate seems to help with Alzheimer's Electronics components have gotten very very cheap in the past few decades On LLM adoption from Zvi Mowshowitz On the wild stories where someone that gets an organ transplant sometimes experience personality changes, and single cell learning. HIV drugs as potential anti-aging drugs Upcoming book about industrial efficiency Alternative to LASIK coming? A first person report of participating in a Phase 1 clinical trial In defense of the Amyloid hypothesis (See previous Nintil posts on Alzheimer's too, though they may be out of date by now). The linked post in Astral Codex Ten is I think mistaken, and one can point to Alnylam's recent failure (No NfL change->no neurodegeneration slowdown) as a more solid test than perhaps the antibodies. It is nonetheless a good presentation of the amyloid cascade hypothesis and why it makes so much sense that amyloid beta is in some way in the etiology of Alzheimer's. The idea that very early prevention could slow down the appearence of AD does make sense to me, but once the disease starts one has to intervene at a different place to stop it. The company I work at is testing a drug for AD later this year in Phase 1, we shall see how that goes! Epigenetic proxies for health biomarkers like LDL fail to pick up changes in a randomized control trial It is argued here that IQ decline happens much slower than commonly assumed. From adderall skeptic to adderall enjoyer